Century Therapeutics Income Statement (2020-2026) | IPSC

Income Statement Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026
Revenue & cost
Revenue (Quarter)
1.06M1.40M2.22M0.52M1.72M0.10M0.15M0.27M0.85M0.77M0.79M4.17M109.16M
Operating items
Amortization - Deferred Charges (Quarter)
0.08M0.08M0.08M0.08M0.08M0.06M0.04M
Research & Development (Quarter)
18.93M19.55M21.80M21.20M24.49M25.90M25.59M24.90M22.73M22.79M22.30M23.42M27.22M27.23M29.38M26.58M26.86M22.53M19.70M17.11M
Wages, Salaries and Other (Quarter)
9.76M10.94M11.06M10.64M9.98M9.71M8.34M5.10M5.60M
Selling, General & Administrative (Quarter)
4.09M6.28M6.18M7.30M8.25M8.06M8.24M8.90M8.23M8.99M8.59M8.74M8.31M8.35M7.75M8.41M7.80M6.83M0.96M6.58M
Other Operating Expenses (Quarter)
10.00M0.10M0.15M13.14M0.77M0.79M4.17M6.76M
Operating Expenses (Quarter)
23.02M25.83M27.97M38.49M32.75M33.96M33.83M33.80M35.18M35.77M44.03M32.16M35.53M35.58M41.46M34.99M34.66M36.12M20.65M23.68M
Operating Income (Quarter)
-23.02M-25.83M-27.97M-37.44M-31.35M-31.74M-33.31M-32.08M-35.08M-35.63M-43.76M-31.31M-34.76M-34.79M74.69M74.18M-34.66M-36.12M-5.41M-23.68M
EBIT (Quarter)
-23.02M-25.83M-27.97M-37.44M-31.35M-31.74M-33.31M-32.08M-35.08M-35.63M-43.76M-31.31M-34.76M-34.79M74.69M74.18M-34.66M-36.12M-5.41M-23.68M
Non-operating items
Interest & Investment Income (Quarter)
0.71M1.41M2.62M3.06M3.49M3.51M3.24M3.58M3.31M2.88M2.42M2.01M1.60M1.31M2.02M
Other Non Operating Income (Quarter)
-0.25M-0.18M-0.18M-0.06M0.01M-0.02M4.44M-0.19M-0.19M0.01M-0.01M0.01M-0.01M0.25M0.11M-0.04M0.11M0.10M0.10M0.02M
Non Operating Income (Quarter)
-0.25M-0.18M-0.18M-0.06M0.38M-0.02M3.01M-0.19M2.74M3.50M12.12M0.01M3.57M0.25M2.99M-0.04M0.11M0.10M7.45M0.02M
Net income details
EBT (Quarter)
-23.27M-26.01M-28.15M-37.50M-30.97M-30.72M-31.65M-30.06M-32.34M-32.13M-40.27M-28.06M-31.18M-31.23M-34.30M76.56M-32.54M-34.42M-9.55M-21.66M
Tax Provisions (Quarter)
0.02M0.02M0.03M0.03M1.20M0.95M0.59M-0.87M0.00M0.02M-0.01M0.91M
Profit After Tax (Quarter)
-23.27M-26.01M-28.19M-37.51M-30.99M-30.75M-31.68M-31.26M-33.29M-32.72M-39.40M-28.06M-31.21M-31.23M-36.07M76.56M-32.54M-34.42M-19.19M-21.64M
Income from Continuing Operations (Quarter)
-23.27M-26.01M-28.15M-37.51M-30.99M-30.75M-31.68M-31.26M-33.29M-32.72M-39.40M-28.06M-31.21M-31.23M-35.20M76.56M-32.54M-34.42M-9.55M-21.66M
Consolidated Net Income (Quarter)
-23.27M-26.01M-28.15M-37.51M-30.99M-30.75M-31.68M-31.26M-33.29M-32.72M-39.40M-28.06M-31.21M-31.23M-35.20M76.56M-32.54M-34.42M-9.55M-21.66M
Income towards Parent Company (Quarter)
-23.27M-26.01M-28.15M-37.51M-30.99M-30.75M-31.68M-31.26M-33.29M-32.72M-39.40M-28.06M-31.21M-31.23M-35.20M76.56M-32.54M-34.42M-9.55M-21.66M
Net Income towards Common Stockholders (Quarter)
-23.27M-26.01M-28.15M-37.51M-30.99M-30.75M-31.68M-31.26M-33.29M-32.72M-39.40M-28.06M-31.21M-31.23M-35.20M76.56M-32.54M-34.42M-9.55M-21.66M
Additional items
EPS (Basic) (Quarter)
-1.93-0.48-0.24-0.66-0.54-0.53-0.55-0.53-0.56-0.55-0.65-0.45-0.38-0.37-0.430.89-0.38-0.40-0.25-0.11
EPS (Weighted Average and Diluted) (Quarter)
-1.93-0.48-0.24-0.66-0.54-0.53-1.24-0.53-0.56-0.55-0.65-0.45-0.38-0.37-0.430.89-0.38-0.40-0.25-0.11
Shares Outstanding (Weighted Average) (Quarter)
12.04M54.47M32.39M57.05M57.69M57.97M57.76M58.61M59.25M59.09M59.31M62.30M72.19M76.39M78.65M86.02M86.24M86.31M86.56M193.47M
Shares Outstanding (Diluted Average) (Quarter)
9.78M54.47M32.39M57.05M57.69M57.97M32.39M58.61M58.90M59.45M59.31M62.30M72.19M76.39M78.65M86.10M86.21M86.39M86.56M193.47M
EBITDA (Quarter)
-23.25M-26.07M-28.78M-39.51M-31.78M-30.92M-30.54M-30.08M-33.22M-32.82M-37.98M-28.41M-31.27M-30.16M-36.51M76.54M-32.76M-34.44M-19.20M-22.26M
Interest Expenses (Quarter)
0.32M0.32M0.32M0.31M0.33M0.30M0.64M0.35M0.14M
Shares Outstanding (Quarter)
54.40M54.64M55.01M57.59M57.86M58.18M58.47M59.11M59.31M59.51M60.34M64.81M84.55M84.76M85.84M86.15M86.32M86.53M87.52M180.10M
Tax Rate (Quarter)
-0.04-0.06-0.08-0.09-3.99-2.94-1.842.150.00-0.070.03-2.64